Genzyme Belgium Genzyme Corporate Search Contact us
HealthcarePatients & FamiliesPractical Info
A disease with many faces
 
Healthcare Professionals
About Lysosomal Storage Disease
Gaucher
Fabry
Disease Information
Management of Fabry Disease
Medical Information Services
Fabry Registry
Practical Info
Request Materials
MPS I
Pompe

 



 

Fabry Disease – Renal Impact

Progressive glycosphingolipid (particularly GL-3) accumulation may lead to irreversible and potentially life-threatening clinical sequelae in the kidney. Renal complications generally herald the end stage of the disease and are the most frequent cause of death among classically affected Fabry patients (hemizygotes).

While GL-3 deposits are primarily found in the lysosomes of the vascular endothelium,[1] renal biopsy studies of young hemizygotes show diffuse lipid accumulation in the glomerular, vascular, and interstitial cells, and tubular involvement primarily in distal convoluted tubules and loops of Henle.[2]

GL-3 accumulation in the Mesangial and Capillary Endothelial Cells of the Glomerulus

With age, intimal thickening and degenerative glomerular and tubular changes are apparent.[2]

Light Micrograph of End-Stage Renal Disease in Fabry Patient

Proteinuria, isosthenuria, and azotemia

Most patients with classical Fabry disease develop proteinuria in late adolescence, which progresses to isosthenuria and alterations of tubular reabsorption, secretion, and excretion.[1] Azotemia usually occurs by the third to fifth decade of life,[1] although renal failure has also been reported in patients as young as 16 years old.[3] Renal complications tend to be less evident in female carriers than in hemizygotes.[4]

Urinalysis is also characterized by hematuria and lipiduria,[5] often beginning in childhood. Polarization microscopy of free urine or urinary sediment reveals birefringent lipid globules with characteristic "Maltese crosses[1] (see also Molcular basis, picture 3)."

References

1. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill, 2001;3733-3774.

2.Gubler M-C, Lenoir G, Grünfeld J-P, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int. 1978;13:223-235.

3. Sheth KJ, Roth DA, Adams MB. Early renal failure in Fabry's disease. Am J Kidney Dis. 1983;II;651-654.

4.Sessa A, Meroni M, Battini G, et al. Renal pathological changes in Fabry disease. J Inher Metab Dis. 2001;24 Suppl 2:66-70.

5. Meroni M, Sessa A, Battini G, Tazzari S, Tarelli LT. Kidney involvement in Anderson-Fabry disease. Contrib Nephrol. 1997;122:178-184.

 
Print

PRINT

Bookmark

BOOKMARK




01/01/2007: Low bone density in Gaucher disease improves with Cerezyme®

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with Fabrazyme® significantly slows progression of Fabry

More >



Lysosomal Storage Disorders
General information
Gaucher Disease
Fabry Disease
MPS I Disease
Pompe Disease